Novo Nordisks oral semaglutide 25 mg (Wegovy in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy®) achieved significant…
Milano Cortina 2026 ramps up excitement as Italy enters final delivery phase
17 September 2025 -Â With just 70 days to go until the Olympic…
Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease
SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering…
Nxera Pharma and Cancer Research UK Announce First Patient Dosed in Phase 2a Trial of Investigational Cancer Immunotherapy HTL0039732
HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist being…
CellPoint Digital Appoints Travel Technology Pioneers Julia Sattel and Kathleen Merrill to Board of Directors
Former Amadeus President and Southwest Airlines SVP & CIO Join Payment Orchestration…
Arkieva announces Anand Iyer as CEO
Supply chain planning veteran brings technical expertise, experience scaling go-to-market functions to…
Q&A WITH FX DEMAISON, GENESIS MAGMA RACING TECHNICAL DIRECTOR AND JUSTIN TAYLOR, GENESIS MAGMA RACING CHIEF ENGINEER
Genesis Magma Racing’s technical leads reflect on the busy first weeks of…
NanoNewron Awarded $2.5 Million in NIH STTR Phase 2 Grant to Advance its Innovative NN-840 Alzheimers Disease Program
The $2.5 Million in NIH STTR Phase 2 Grant allows NanoNewron to…
Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints
SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd…
Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism
September 06, 2025 14:30 ET Â | Source: BridgeBio Pharma, Inc. - 80%…